At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 89 enrolled
Drug / intervention
Erenumab +1 moredrug
Likely dose
Erenumab 140 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of AMG 334 on Exercise Time During a Treadmill Test in Subjects With Stable Angina
In Brief
A Phase 2 clinical trial evaluating Erenumab and Placebo for Stable Angina. Completed, enrolled 89 participants across 33 sites in 10 countries.
Detailed Summary
A phase 2a, multicenter, randomized, double-blind, placebo-controlled study in adults with stable angina to evaluate the effect of erenumab (AMG 334) compared to placebo on exercise time during an exercise treadmill test.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStable Angina
CountriesBulgaria, Czechia, Latvia, New Zealand, Poland, Romania, Slovakia, South Africa, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartNov 2015
Primary CompletionJan 2017
Study CompletionApr 2017
TodayJul 2026
First PostedOct 15, 2015
Enrollment StartNov 23, 2015
Primary CompletionJan 23, 2017
Study CompletionApr 13, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.7 years ago
Interventions
Erenumabdrug
A single dose of erenumab 140 mg infused over approximately 60 minutes.
Placebodrug
A single dose of a matching volume of placebo infused over approximately 60 minutes.